Leadership

CONTACT US

Babylon BioConsulting LLC

1712 Pioneer Avenue

Suite 1008

Cheyenne, WY 82001
Phone: 913-909-1128
Fax: 888-385-9109

Email: info@babylonbioconsulting.com

Samer Al-Murrani, Ph.D., M.B.A.,
Chief Executive Officer

Dr. Al-MUrrani, has over 25 years of life science research and management within academia and industry. He also is Managing Director of Bimini LLC an animal health company and a manufacturer of pet dose form health supplements and health treats. His extensive business management expertise is focused on executive coaching, start-up business funding and investor outreach, early-stage animal health company valuations and investor due diligence, intangible asset management and the FDA/CVM driven regulatory requirements for multiple industries. He has excellent negotiation skills and has successfully negotiated multi-million dollar research, purchasing and intellectual property licensing contracts, advised on patent applications and provided subject matter expertise. Dr. Al-Murrani’s contacts and bilingual background is especially well suited to helping U.S. and European based life science human and animal health companies penetrate emerging markets in the Middle East and global companies to enter and become established in the U.S. He has advised and worked closely with healthcare-centered marketing, advertising and PR firms to help develop targeted communication pieces for specific populations and professional segments. Dr. Al-Murrani is also a member of the advisory board for the International Animal Health Journal which is published quarterly by Pharma Publications.

Dr. Al-Murrani is recognized as an industry and technical expert with numerous editorials and articles in various industry and scientific peer reviewed journals, including International Animal Health Journal, Molecular and Cellular Biology (MCB), the Journal of Biological Chemistry (JBC), Biochemistry, BMC Genomics and the Journal of Feline Medicine and Surgery. His work also includes a book chapter on Nutritional Genomics in Health and Disease, which appears in the 5th edition of Small Animal Clinical Nutrition. Dr. Al-Murrani is also the sole inventor of several granted patents relating to the discovery of potential diagnostic, prognostic and theranostic targets in ovarian cancer and colon cancer patients and diagnostic targets for feline degenerative joint disease (US 7,700,280; 8,192,935, 8,759,258, EP 1,704,250 and ZL 201110195193.7).

Dr. Al-Murrani earned his undergraduate degree in animal science from the University of Edinburgh and completed his Ph.D. in immunology/biochemistry at the Roslin Institute and the Department of Veterinary Pathology at the University of Edinburgh. He holds an M.B.A. in finance from Baker University.

Dr. Michael R. Pisano, Ph.D.

Senior Member - Advisory Board

Dr. Michael Pisano has global senior management experience in the life sciences industry and is currently Vice President of Biochemistry at Cayman Chemical. Dr. Pisano holds a Ph.D. in Biochemistry and has extensive experience as a senior manager who has successfully led and driven strategic growth in organizations in order to create value for company stakeholders.

Dr. Pisano has over 20 years of industrial experience including senior management positions in large pharmaceutical companies as well as instrumentation, biochemical consumables and contract research and services companies. Industry positions held include CEO, CSO and Board Member, NextGen Group, PLC; President, CEO and Board Member, NextGen Sciences, Inc.; Co-Founder, President, CEO and Director Proteomic Research Services, Inc.; Vice President, R&D, Genomic Solutions, Inc.; Head, Protein Sciences, Aventis Phar

maceuticals; Section Manager, Core Biotechnologies Department, Biochemistry Group and Group Leader, Biochemistry Group Gene Medicine Department Rhone-Poulenc Rorer Pharmaceuticals; Research Scientist, Department of Structural Biology, Core Biotechnology, Wyeth Pharmaceuticals.

Fully led and driven strategic growth in organizations in order to create value for company stakeholders. Dr. Pisano has been an invited speaker at many international conferences. He was also invited to organize and present at a Grand Rounds day at the FDA (the topic was "Biomarkers in Drug Development"). Dr. Pisano has also served as a member of the Quebec Consortium for Drug Discovery (CQDM) - Fonds de la Recherche en Sante du Quebec FRSQ Review Committee, on Scientific Advisory Boards of life science companies and instrumentation manufacturers and as a member of the Michigan University Commercialization Committee. Dr. Pisano earned his B.S. in biology from the University of Dayton and completed his Ph.D. in Biochemistry at the Univeersity of Toledo College of Medicine (formerly the Medical College of Ohio).